Low dose methods for treating disorders in which TNFalpha activity is detrimental
AssigneeAbbVie Biotechnology Ltd.
InventorsZehra Kaymakcalan, Robert Kamen
Life of this patent
Estimating the term…
Abstract
A method of treating TNFα disorders is described, wherein the method comprises administering a low dose amount of a TNFα inhibitor.
Claims31
A method for treating a disorder in which TNFα activity is detrimental comprising administering to a subject an effective amount of a TNFα inhibitor in a low dose therapy, such that the disorder is treated.
A method to alleviate symptoms associated with a disorder in which TNFα activity is detrimental, comprising administering a low dose of a TNFα inhibitor to a subject suffering from said disorder, such that the symptoms are treated.
A method for treating arthritis comprising administering to a subject an effective amount of a TNFα inhibitor in a low dose therapy, such that the arthritis is treated.
A method for treating symptoms associated with arthritis comprising administering to a subject a low dose of an effective amount of a TNFα inhibitor, such that the symptoms are alleviated.
A method of sequestering TNFα into complexes in a subject suffering from a disorder in which TNFα activity is detrimental, by administering a low dose of a TNFα inhibitor to the subject.
Dependencies are inferred from the claim text.